SlideShare a Scribd company logo
 
DIABETES  MELLITUS DR AFTAB AHMED RAJPUT  FCPS PART 2 TRAINEE  MEDICAL UNIT 2 PMCH,NAWAB SHAH
PRESENTATION  OUTLINES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
DIABETES MELITUS ,[object Object]
CURRENT IMPACT OF DM ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLASSIFICATION OF DM ,[object Object],[object Object],[object Object],[object Object]
CLASSIFICATION ,[object Object],[object Object]
CONTI…….. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CONTI…… ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CONTI…… ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PATHOPHYSIOLOGGY OF DM ,[object Object],[object Object],[object Object],[object Object]
Pancreatic Hormones ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
EFFECTS OF INSULIN
 
CONTIN……. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Pathophysiology of type 1 diabetes
 
Type One Diabetes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pathophysiology of type 2 diabetes
 
Type Two Diabetes ,[object Object],[object Object],[object Object],[object Object]
What is Insulin Resistance? ,[object Object],[object Object],[object Object]
Insulin resistance syndrome (syndrome x,metabolic syndrome,REAVEN’S SYNDROME) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Type 2 Diabetes Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Characteristics of Diabetes Type 1    Type 2 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLINICAL FEATURES OF DM ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetes Mellitus Type 1 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetes Mellitus Type 2 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
INVESTIGATION AND LABORATORY FINDINGS ,[object Object],[object Object],[object Object]
URINALYSIS ,[object Object],[object Object],[object Object]
Blood tests ,[object Object],[object Object],[object Object]
Other test ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
DIAGNOSTIC CRITERIA FOR DM ,[object Object],[object Object],[object Object],[object Object],[object Object]
GTT ,[object Object],[object Object],[object Object],[object Object],[object Object]
Impaired Fasting Glucose (IFG) ,[object Object],[object Object],[object Object],[object Object]
Impaired Glucose Tolerance (IGT) ,[object Object],[object Object],[object Object],[object Object],[object Object]
MANAGEMENT OF DM
Cornerstones of Diabetes Management ,[object Object],[object Object],[object Object],[object Object],[object Object]
Management of Diabetes ,[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetes Mellitus ,[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetes Mellitus ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetes Mellitus ,[object Object],[object Object],[object Object],[object Object]
Exercise & Weight Loss ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Oral Hypoglycemics
Oral Hypoglycemics ,[object Object],[object Object],[object Object],[object Object]
Oral Anti-Diabetic Agents Sulfonylureas Drugs other than  Sulfonylurea
Sulfonylureas (Oral Hypoglycemic drugs) Tolbutamide Acetohexamide Tolazamide Chlorpropamide Glipizide Glyburide (Glibenclamide) Glimepiride Short acting First generation Intermediate acting Long acting Long acting Short acting Second generation
FIRST GENERATION SULPHONYLUREA COMPOUNDS *  Good for pts with renal impairment **   Pts with renal impairment can expect long t1/2   Tolbutamid  short-acting Acetohexamide intermediate-acting  Tolazamide  intermediate-acting Chlorpropamide long- acting  Absorption Well Well Slow Well Metabolism Yes Yes Yes Yes Metabolites Inactive * Active +++  ** Active ++  ** Inactive  ** Half-life 4 - 5 hrs 6 – 8 hrs 7 hrs 24 – 40 hrs Duration of action Short (6 – 8 hrs) Intermediate  (12 – 20 hrs) Intermediate  (12 – 18 hrs) Long ( 20 – 60 hrs) Excretion Urine Urine Urine Urine
SECOND GENERATION SULPHONYLUREA COMPOUNDS Glipizide Short- acting Glibenclamide (Glyburide) Long-acting Glimepiride Long-acting Absorption Well Well Well Metabolism Yes Yes Yes Metabolites Inactive Inactive Inactive Half-life 3 – 4 hrs Less than 3 hrs 5 - 9 hrs Duration of action 10 – 16 hrs 12 – 24 hrs 12 – 24 hrs Excretion Urine Urine Urine
MECHANISM OF  ACTION OF SULPHONYLUREAS 1) Release of insulin from β-cells 2) Reduction of serum glucagon concentration 3) Potentiation of insulin action on target tissues
SIDE EFFECTS OF SULPHONYLUREAS 1) Nausea, vomiting, abdominal pain, diarrhea 2) Hypoglycaemia 3) Dilutional hyponatraemia & water intoxication  (Chlorpropamide) 4) Weight gain
CONTRAINDICATIONS  OF SULPHONYLUREAS 1) Type 1 DM ( insulin dependent) 2) Parenchymal disease of the liver or kidney 3) Pregnancy, lactation 4) Major stress
Drugs other than Sulfonylurea  Metformin Biguanides α-Glucosidase Inhibitors Thiazolidinediones Acarbose Rosiglitazone Pioglitazone Repaglinide Nateglinide Meglitinides
MEGLITINIDES e.g.  Repaglinide, Nateglinide PHARMACOKINETICS Taken orally Rapidly absorbed ( Peak approx. 1hr ) Metabolized by liver t 1/2  = 1 hr Duration of action  4-5 hr
MEGLITINIDES (Contd.) MECHANISM OF ACTION Bind to the same K ATP  Channel  as do Sulfonylureas,  to cause insulin release from  β-cells.
MEGLITINIDES (Contd.) CLINICAL USE Approved as monotherapy and in combination with metformin in type 2 diabetes Taken before each meal, 3 times / day Does not offer any advantage over sulfonylureas; Advantage: Pts. allergic to sulfur or sulfonylurea SIDE EFFECTS: Hypoglycemia Wt gain ( less than SUs ) Caution in pts with renal & hepatic impairement.
BIGUANIDES e.g. Metformin PHARMACOKINETICS Given orally Not bind to plasma proteins Not metabolized Excreted unchanged in urine t  1/2  2 hr
BIGUANIDES (Contd.) MECHANISM OF ACTION 1. Increase peripheral glucose utilization 2. Inhibits gluconeogenesis 3. Impaired absorption of glucose from the gut
[object Object],[object Object],[object Object],[object Object]
BIGUANIDES (Contd.) SIDE EFFECTS 1. Metallic taste in the mouth 2. Gastrointestinal (anorexia, nausea, vomiting, diarrhea, abdominal discomfort)  3. Vitamin B  12  deficiency (prolonged use) 4. Lactic acidosis ( rare – 01/ 30,000-exclusive in renal & hepatic failure)
1. Hepatic impairment 2. Renal impairment 3. Alcoholism 4. Heart failure BIGUANIDES (Contd.) CONTRAINDICATIONS
[object Object],[object Object],BIGUANIDES (Contd.) INDICATIONS
α-GLUCOSIDASE INHIBITORS e.g. Acarbose PHARMACOKINETICS Given orally Not absorbed from intestine except small amount t 1/2  3 - 7 hr Excreted with stool
MECHANISM OF ACTION Inhibits intestinal alpha-glucosidases and  delays carbohydrate absorption, reducing postprandial   increase in blood glucose α-GLUCOSIDASE INHIBITORS (Contd.)
SIDE EFFECTS Flatulence Loose stool or diarrhea Abdominal pain Alone does not cause hypoglycemia α-GLUCOSIDASE INHIBITORS (Contd.)
INDICATIONS Patients with Type 11 inadequately controlled by  diet with or without other agents( SU, Metformin) Can be combined with insulin may be helpful in obese Type 11 patients  (similar to metformin) α-GLUCOSIDASE INHIBITORS (Contd.)
THIAZOLIDINEDIONE DERIVATIVES New class of oral antidiabetics e.g.:   Rosiglitazone Pioglitazone
PHARMACOKINETICS ,[object Object],[object Object],[object Object],[object Object],[object Object],THIAZOLIDINEDIONE DERIVATIVES (Contd.)
MECHANISM OF ACTION ,[object Object],[object Object],[object Object],THIAZOLIDINEDIONE DERIVATIVES (Contd.)
ADVERSE EFFECTS ,[object Object],[object Object],[object Object],[object Object],[object Object],THIAZOLIDINEDIONE DERIVATIVES (Contd.)
INDICATIONS Type 11 diabetes alone or in combination with  metformin or sulfonylurea or insulin in patients resistant to insulin treatment. THIAZOLIDINEDIONE DERIVATIVES (Contd.)
DPP-4 Inhibitor ,[object Object],[object Object],[object Object],[object Object]
Incretin Hormones ,[object Object],[object Object],[object Object],[object Object]
DPP-4 Inhibitor ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
Diabetes Mellitus ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
TYPES OF INSULIN  PREPARATIONS 1. Ultra-short-acting  2.  Short-acting (Regular) 3.  Intermediate-acting 4.  Long-acting
 
3. Intermediate - acting insulins e.g.  isophane (NPH) Turbid suspension Injected S.C.(Only) Onset of action 1 - 2 hr Peak serum level 5 - 7 hr Duration of action 13 - 18 hr Insulin mixtures 75/25  70/30  50/50  ( NPH / Regular )
3. Intermediate - acting insulins (contd.) Lente insulin Turbid suspension Mixture of 30% semilente insulin 70% ultralente insulin Injected S.C. (only) Onset of action 1 - 3 hr Peak serum  level 4 - 8 hr Duration of action 13 - 20 hr
3. Intermediate - acting insulins (contd.) Lente and NPH insulins  Are roughly equivalent in biological effects. They are usually given once or twice a day. N.B: They are not used during emergencies     (e.g. diabetic ketoacidosis).
4. Long – acting insulins e.g.Insulin glargine Onset of action 2 hr Absorbed less rapidly than NPH&Lente insulins. Duration of action upto 24 hr Designed to overcome the deficiencies of intermediate acting insulins   Advantages over intermediate-acting insulins: Constant circulating insulin over 24hr with no pronounced peak. More safe than NPH&Lente insulins due to reduced risk of hypoglycemia(esp.nocturnal hypoglycemia). Clear solution that does not require resuspention before administration.
Methods of Adminisration ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
COMPLICATIONS OF INSULIN THERAPY 1.  Severe Hypoglycemia (< 50 mg/dl )– Life threatening Overdose of insulin Excessive (unusual) physical exercise A  meal is missed 2.  Weight gain  3. Local or systemic allergic reactions (rare)  4. Lipodystrophy at injection sites  5. Insulin resistance 6. Hypokalemia
 

More Related Content

What's hot

Complications of Diabetes Mellitus
Complications of Diabetes MellitusComplications of Diabetes Mellitus
Complications of Diabetes Mellitus
Carmela Domocmat
 
Diabetes treatment
Diabetes treatmentDiabetes treatment
Diabetes treatment
PranatiChavan
 
Diabetis ppt
Diabetis pptDiabetis ppt
Diabetis ppt
Asraful Islam Rayhan
 
Diabetes Powerpoint 6
Diabetes  Powerpoint 6Diabetes  Powerpoint 6
Diabetes Powerpoint 6
Chocolate42
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Saran Adgiri
 
Diabetes Mellitus
Diabetes Mellitus Diabetes Mellitus
Diabetes Mellitus
Angel Belle
 
APPROACH TO DIABETES
APPROACH TO DIABETESAPPROACH TO DIABETES
APPROACH TO DIABETES
Arabinda Mohanty
 
Diabetes mellitus presentation
Diabetes mellitus presentationDiabetes mellitus presentation
Diabetes mellitus presentation
lakshmi das
 
Obesity - Pathophysiology, Etiology and management
Obesity - Pathophysiology, Etiology and management Obesity - Pathophysiology, Etiology and management
Obesity - Pathophysiology, Etiology and management
Aneesh Bhandary
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
Jack Frost
 
Etiology & pathogenesis of Diabetes Mellitus
Etiology & pathogenesis of Diabetes MellitusEtiology & pathogenesis of Diabetes Mellitus
Etiology & pathogenesis of Diabetes Mellitus
Eneutron
 
Hypoglycemia- Assessment and Treatment
Hypoglycemia- Assessment and TreatmentHypoglycemia- Assessment and Treatment
Hypoglycemia- Assessment and Treatment
Bangabandhu Sheikh Mujib Medical University
 
Diabetes mellitus
Diabetes mellitus Diabetes mellitus
Diabetes mellitus
Jyoti Gaver
 
Diabetes Mellitus (DM)
Diabetes Mellitus (DM)Diabetes Mellitus (DM)
Diabetes Mellitus (DM)
Abhay Rajpoot
 
Type 2 dm
Type 2 dmType 2 dm
Type 2 dm
Drmukesh Samota
 
9. metabolic syndrome
9. metabolic syndrome9. metabolic syndrome
9. metabolic syndrome
Madhumita Sen
 
Diabetes mellitus definition,classification,clinical features ,investigation
Diabetes mellitus definition,classification,clinical features ,investigationDiabetes mellitus definition,classification,clinical features ,investigation
Diabetes mellitus definition,classification,clinical features ,investigationFarrukh Masood
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
GAMANDEEP
 

What's hot (20)

Complications of Diabetes Mellitus
Complications of Diabetes MellitusComplications of Diabetes Mellitus
Complications of Diabetes Mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes treatment
Diabetes treatmentDiabetes treatment
Diabetes treatment
 
2. diabetes mellitus
2. diabetes mellitus2. diabetes mellitus
2. diabetes mellitus
 
Diabetis ppt
Diabetis pptDiabetis ppt
Diabetis ppt
 
Diabetes Powerpoint 6
Diabetes  Powerpoint 6Diabetes  Powerpoint 6
Diabetes Powerpoint 6
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes Mellitus
Diabetes Mellitus Diabetes Mellitus
Diabetes Mellitus
 
APPROACH TO DIABETES
APPROACH TO DIABETESAPPROACH TO DIABETES
APPROACH TO DIABETES
 
Diabetes mellitus presentation
Diabetes mellitus presentationDiabetes mellitus presentation
Diabetes mellitus presentation
 
Obesity - Pathophysiology, Etiology and management
Obesity - Pathophysiology, Etiology and management Obesity - Pathophysiology, Etiology and management
Obesity - Pathophysiology, Etiology and management
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Etiology & pathogenesis of Diabetes Mellitus
Etiology & pathogenesis of Diabetes MellitusEtiology & pathogenesis of Diabetes Mellitus
Etiology & pathogenesis of Diabetes Mellitus
 
Hypoglycemia- Assessment and Treatment
Hypoglycemia- Assessment and TreatmentHypoglycemia- Assessment and Treatment
Hypoglycemia- Assessment and Treatment
 
Diabetes mellitus
Diabetes mellitus Diabetes mellitus
Diabetes mellitus
 
Diabetes Mellitus (DM)
Diabetes Mellitus (DM)Diabetes Mellitus (DM)
Diabetes Mellitus (DM)
 
Type 2 dm
Type 2 dmType 2 dm
Type 2 dm
 
9. metabolic syndrome
9. metabolic syndrome9. metabolic syndrome
9. metabolic syndrome
 
Diabetes mellitus definition,classification,clinical features ,investigation
Diabetes mellitus definition,classification,clinical features ,investigationDiabetes mellitus definition,classification,clinical features ,investigation
Diabetes mellitus definition,classification,clinical features ,investigation
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 

Viewers also liked

Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
MD Abdul Haleem
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
rohini sane
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Rikha Decha
 
All what you have to know about Diabetes Mellitus
All what you have to know about Diabetes MellitusAll what you have to know about Diabetes Mellitus
All what you have to know about Diabetes Mellitus
Yapa
 
Diabetes Mellitus and Insuline analogs
Diabetes Mellitus and Insuline analogsDiabetes Mellitus and Insuline analogs
Diabetes Mellitus and Insuline analogs
Abubakkar Raheel
 
Diabetes mellitus by dr shahjada selim
Diabetes mellitus by dr shahjada selimDiabetes mellitus by dr shahjada selim
Diabetes mellitus by dr shahjada selim
Bangabandhu Sheikh Mujib Medical University
 
Diabetes Mellitus - In Terms of Biochemistry
Diabetes Mellitus - In Terms of BiochemistryDiabetes Mellitus - In Terms of Biochemistry
Diabetes Mellitus - In Terms of Biochemistry
Ashok Katta
 
Diabetes mellitus & oral surgery
Diabetes mellitus & oral surgeryDiabetes mellitus & oral surgery
Diabetes mellitus & oral surgerykamini singh
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Sara Ravi
 
Pharmacotherapy of diabetes mellitus
Pharmacotherapy of diabetes mellitusPharmacotherapy of diabetes mellitus
Pharmacotherapy of diabetes mellitus
Naser Tadvi
 
DIABETES MELLITUS - BIOCHEMISTRY
DIABETES MELLITUS - BIOCHEMISTRYDIABETES MELLITUS - BIOCHEMISTRY
DIABETES MELLITUS - BIOCHEMISTRY
YESANNA
 
Diabetes mellitus- Dr Sanjana Ravindra
Diabetes mellitus- Dr Sanjana Ravindra Diabetes mellitus- Dr Sanjana Ravindra
Diabetes mellitus- Dr Sanjana Ravindra
Dr. Sanjana Ravindra
 
Diabetes ppt
Diabetes pptDiabetes ppt
Diabetes ppt
Tavo1021
 
Diabetes powerpoint
Diabetes powerpointDiabetes powerpoint
Diabetes powerpointmldanforth
 

Viewers also liked (17)

Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
All what you have to know about Diabetes Mellitus
All what you have to know about Diabetes MellitusAll what you have to know about Diabetes Mellitus
All what you have to know about Diabetes Mellitus
 
Diabetes Mellitus and Insuline analogs
Diabetes Mellitus and Insuline analogsDiabetes Mellitus and Insuline analogs
Diabetes Mellitus and Insuline analogs
 
Diabetes mellitus by dr shahjada selim
Diabetes mellitus by dr shahjada selimDiabetes mellitus by dr shahjada selim
Diabetes mellitus by dr shahjada selim
 
Diabetes Mellitus - In Terms of Biochemistry
Diabetes Mellitus - In Terms of BiochemistryDiabetes Mellitus - In Terms of Biochemistry
Diabetes Mellitus - In Terms of Biochemistry
 
Type 1 Diabetes
Type 1 Diabetes Type 1 Diabetes
Type 1 Diabetes
 
Diabetes mellitus & oral surgery
Diabetes mellitus & oral surgeryDiabetes mellitus & oral surgery
Diabetes mellitus & oral surgery
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Pharmacotherapy of diabetes mellitus
Pharmacotherapy of diabetes mellitusPharmacotherapy of diabetes mellitus
Pharmacotherapy of diabetes mellitus
 
DIABETES MELLITUS - BIOCHEMISTRY
DIABETES MELLITUS - BIOCHEMISTRYDIABETES MELLITUS - BIOCHEMISTRY
DIABETES MELLITUS - BIOCHEMISTRY
 
Diabetes mellitus- Dr Sanjana Ravindra
Diabetes mellitus- Dr Sanjana Ravindra Diabetes mellitus- Dr Sanjana Ravindra
Diabetes mellitus- Dr Sanjana Ravindra
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugs
 
Diabetes ppt
Diabetes pptDiabetes ppt
Diabetes ppt
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes powerpoint
Diabetes powerpointDiabetes powerpoint
Diabetes powerpoint
 

Similar to DIABETES MELLITUS by dr aftab ahmed

Intro to Endocrine Disorder Unit-II.ppt
Intro to Endocrine Disorder Unit-II.pptIntro to Endocrine Disorder Unit-II.ppt
Intro to Endocrine Disorder Unit-II.ppt
HiraKhan218459
 
SEMINAR PRESENTATION.pptx dmmm.pptx
SEMINAR PRESENTATION.pptx dmmm.pptxSEMINAR PRESENTATION.pptx dmmm.pptx
SEMINAR PRESENTATION.pptx dmmm.pptx
MebratGebreyesus
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
Shine Thenu
 
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase MethodDetermination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Zoldylck
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
Jack Frost
 
Diabetes_.pptx
Diabetes_.pptxDiabetes_.pptx
Diabetes_.pptx
ChiragPatil55
 
Diabetes and oral health 2020
Diabetes and oral health 2020Diabetes and oral health 2020
Diabetes and oral health 2020
SamyAbdulHakiem
 
2023 Diabetes Mellitus.pptx
2023 Diabetes Mellitus.pptx2023 Diabetes Mellitus.pptx
2023 Diabetes Mellitus.pptx
NimonaAAyele
 
Diabetes &amp; glycemic disorders
Diabetes &amp; glycemic disordersDiabetes &amp; glycemic disorders
Diabetes &amp; glycemic disorders
me2432 j
 
Pathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitusPathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitus
niva niva
 
Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementMedicineAndFamily
 
Diabetes - diagnosis,complication and monitoring by Dr Prabhash
Diabetes - diagnosis,complication and monitoring by Dr PrabhashDiabetes - diagnosis,complication and monitoring by Dr Prabhash
Diabetes - diagnosis,complication and monitoring by Dr Prabhash
Prabhash Bhavsar
 
DIABETES MELLITUS.ppt
DIABETES MELLITUS.pptDIABETES MELLITUS.ppt
DIABETES MELLITUS.ppt
malti19
 
Diabetes Diagnosis and Classification
Diabetes Diagnosis and ClassificationDiabetes Diagnosis and Classification
Diabetes Diagnosis and Classification
DR. VIVEK ARYA
 
Epidemiology of diabetes mellitus
Epidemiology of diabetes mellitusEpidemiology of diabetes mellitus
Epidemiology of diabetes mellitus
mgmcricommunitymed
 
Diabetes and Glucose Metabolism
Diabetes and Glucose MetabolismDiabetes and Glucose Metabolism
Diabetes and Glucose MetabolismPatrick Carter
 
DIABETES at a glance.pptx
DIABETES at a glance.pptxDIABETES at a glance.pptx
DIABETES at a glance.pptx
AKENUWAHILDA
 
Medicine 5th year, all lectures/diabetes mellitus (Dr. Taha Mahwy)
Medicine 5th year, all lectures/diabetes mellitus (Dr. Taha Mahwy)Medicine 5th year, all lectures/diabetes mellitus (Dr. Taha Mahwy)
Medicine 5th year, all lectures/diabetes mellitus (Dr. Taha Mahwy)
College of Medicine, Sulaymaniyah
 
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptxEPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
DrHarimuBargayary
 

Similar to DIABETES MELLITUS by dr aftab ahmed (20)

Intro to Endocrine Disorder Unit-II.ppt
Intro to Endocrine Disorder Unit-II.pptIntro to Endocrine Disorder Unit-II.ppt
Intro to Endocrine Disorder Unit-II.ppt
 
SEMINAR PRESENTATION.pptx dmmm.pptx
SEMINAR PRESENTATION.pptx dmmm.pptxSEMINAR PRESENTATION.pptx dmmm.pptx
SEMINAR PRESENTATION.pptx dmmm.pptx
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase MethodDetermination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes_.pptx
Diabetes_.pptxDiabetes_.pptx
Diabetes_.pptx
 
Diabetes and oral health 2020
Diabetes and oral health 2020Diabetes and oral health 2020
Diabetes and oral health 2020
 
2023 Diabetes Mellitus.pptx
2023 Diabetes Mellitus.pptx2023 Diabetes Mellitus.pptx
2023 Diabetes Mellitus.pptx
 
Diabetes &amp; glycemic disorders
Diabetes &amp; glycemic disordersDiabetes &amp; glycemic disorders
Diabetes &amp; glycemic disorders
 
Pathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitusPathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitus
 
Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental management
 
Diabetes - diagnosis,complication and monitoring by Dr Prabhash
Diabetes - diagnosis,complication and monitoring by Dr PrabhashDiabetes - diagnosis,complication and monitoring by Dr Prabhash
Diabetes - diagnosis,complication and monitoring by Dr Prabhash
 
DIABETES MELLITUS.ppt
DIABETES MELLITUS.pptDIABETES MELLITUS.ppt
DIABETES MELLITUS.ppt
 
Diabetes Diagnosis and Classification
Diabetes Diagnosis and ClassificationDiabetes Diagnosis and Classification
Diabetes Diagnosis and Classification
 
Dm 1 1
Dm 1 1Dm 1 1
Dm 1 1
 
Epidemiology of diabetes mellitus
Epidemiology of diabetes mellitusEpidemiology of diabetes mellitus
Epidemiology of diabetes mellitus
 
Diabetes and Glucose Metabolism
Diabetes and Glucose MetabolismDiabetes and Glucose Metabolism
Diabetes and Glucose Metabolism
 
DIABETES at a glance.pptx
DIABETES at a glance.pptxDIABETES at a glance.pptx
DIABETES at a glance.pptx
 
Medicine 5th year, all lectures/diabetes mellitus (Dr. Taha Mahwy)
Medicine 5th year, all lectures/diabetes mellitus (Dr. Taha Mahwy)Medicine 5th year, all lectures/diabetes mellitus (Dr. Taha Mahwy)
Medicine 5th year, all lectures/diabetes mellitus (Dr. Taha Mahwy)
 
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptxEPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
 

Recently uploaded

The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
Tamralipta Mahavidyalaya
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 

Recently uploaded (20)

The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 

DIABETES MELLITUS by dr aftab ahmed

  • 1.  
  • 2. DIABETES MELLITUS DR AFTAB AHMED RAJPUT FCPS PART 2 TRAINEE MEDICAL UNIT 2 PMCH,NAWAB SHAH
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 14.  
  • 15.
  • 16.
  • 18.  
  • 19.
  • 21.  
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 48.
  • 49. Oral Anti-Diabetic Agents Sulfonylureas Drugs other than Sulfonylurea
  • 50. Sulfonylureas (Oral Hypoglycemic drugs) Tolbutamide Acetohexamide Tolazamide Chlorpropamide Glipizide Glyburide (Glibenclamide) Glimepiride Short acting First generation Intermediate acting Long acting Long acting Short acting Second generation
  • 51. FIRST GENERATION SULPHONYLUREA COMPOUNDS * Good for pts with renal impairment ** Pts with renal impairment can expect long t1/2 Tolbutamid short-acting Acetohexamide intermediate-acting Tolazamide intermediate-acting Chlorpropamide long- acting Absorption Well Well Slow Well Metabolism Yes Yes Yes Yes Metabolites Inactive * Active +++ ** Active ++ ** Inactive ** Half-life 4 - 5 hrs 6 – 8 hrs 7 hrs 24 – 40 hrs Duration of action Short (6 – 8 hrs) Intermediate (12 – 20 hrs) Intermediate (12 – 18 hrs) Long ( 20 – 60 hrs) Excretion Urine Urine Urine Urine
  • 52. SECOND GENERATION SULPHONYLUREA COMPOUNDS Glipizide Short- acting Glibenclamide (Glyburide) Long-acting Glimepiride Long-acting Absorption Well Well Well Metabolism Yes Yes Yes Metabolites Inactive Inactive Inactive Half-life 3 – 4 hrs Less than 3 hrs 5 - 9 hrs Duration of action 10 – 16 hrs 12 – 24 hrs 12 – 24 hrs Excretion Urine Urine Urine
  • 53. MECHANISM OF ACTION OF SULPHONYLUREAS 1) Release of insulin from β-cells 2) Reduction of serum glucagon concentration 3) Potentiation of insulin action on target tissues
  • 54. SIDE EFFECTS OF SULPHONYLUREAS 1) Nausea, vomiting, abdominal pain, diarrhea 2) Hypoglycaemia 3) Dilutional hyponatraemia & water intoxication (Chlorpropamide) 4) Weight gain
  • 55. CONTRAINDICATIONS OF SULPHONYLUREAS 1) Type 1 DM ( insulin dependent) 2) Parenchymal disease of the liver or kidney 3) Pregnancy, lactation 4) Major stress
  • 56. Drugs other than Sulfonylurea Metformin Biguanides α-Glucosidase Inhibitors Thiazolidinediones Acarbose Rosiglitazone Pioglitazone Repaglinide Nateglinide Meglitinides
  • 57. MEGLITINIDES e.g. Repaglinide, Nateglinide PHARMACOKINETICS Taken orally Rapidly absorbed ( Peak approx. 1hr ) Metabolized by liver t 1/2 = 1 hr Duration of action 4-5 hr
  • 58. MEGLITINIDES (Contd.) MECHANISM OF ACTION Bind to the same K ATP Channel as do Sulfonylureas, to cause insulin release from β-cells.
  • 59. MEGLITINIDES (Contd.) CLINICAL USE Approved as monotherapy and in combination with metformin in type 2 diabetes Taken before each meal, 3 times / day Does not offer any advantage over sulfonylureas; Advantage: Pts. allergic to sulfur or sulfonylurea SIDE EFFECTS: Hypoglycemia Wt gain ( less than SUs ) Caution in pts with renal & hepatic impairement.
  • 60. BIGUANIDES e.g. Metformin PHARMACOKINETICS Given orally Not bind to plasma proteins Not metabolized Excreted unchanged in urine t 1/2 2 hr
  • 61. BIGUANIDES (Contd.) MECHANISM OF ACTION 1. Increase peripheral glucose utilization 2. Inhibits gluconeogenesis 3. Impaired absorption of glucose from the gut
  • 62.
  • 63. BIGUANIDES (Contd.) SIDE EFFECTS 1. Metallic taste in the mouth 2. Gastrointestinal (anorexia, nausea, vomiting, diarrhea, abdominal discomfort) 3. Vitamin B 12 deficiency (prolonged use) 4. Lactic acidosis ( rare – 01/ 30,000-exclusive in renal & hepatic failure)
  • 64. 1. Hepatic impairment 2. Renal impairment 3. Alcoholism 4. Heart failure BIGUANIDES (Contd.) CONTRAINDICATIONS
  • 65.
  • 66. α-GLUCOSIDASE INHIBITORS e.g. Acarbose PHARMACOKINETICS Given orally Not absorbed from intestine except small amount t 1/2 3 - 7 hr Excreted with stool
  • 67. MECHANISM OF ACTION Inhibits intestinal alpha-glucosidases and delays carbohydrate absorption, reducing postprandial increase in blood glucose α-GLUCOSIDASE INHIBITORS (Contd.)
  • 68. SIDE EFFECTS Flatulence Loose stool or diarrhea Abdominal pain Alone does not cause hypoglycemia α-GLUCOSIDASE INHIBITORS (Contd.)
  • 69. INDICATIONS Patients with Type 11 inadequately controlled by diet with or without other agents( SU, Metformin) Can be combined with insulin may be helpful in obese Type 11 patients (similar to metformin) α-GLUCOSIDASE INHIBITORS (Contd.)
  • 70. THIAZOLIDINEDIONE DERIVATIVES New class of oral antidiabetics e.g.: Rosiglitazone Pioglitazone
  • 71.
  • 72.
  • 73.
  • 74. INDICATIONS Type 11 diabetes alone or in combination with metformin or sulfonylurea or insulin in patients resistant to insulin treatment. THIAZOLIDINEDIONE DERIVATIVES (Contd.)
  • 75.
  • 76.
  • 77.
  • 78.
  • 79.
  • 80.
  • 81.  
  • 82. TYPES OF INSULIN PREPARATIONS 1. Ultra-short-acting 2. Short-acting (Regular) 3. Intermediate-acting 4. Long-acting
  • 83.  
  • 84. 3. Intermediate - acting insulins e.g. isophane (NPH) Turbid suspension Injected S.C.(Only) Onset of action 1 - 2 hr Peak serum level 5 - 7 hr Duration of action 13 - 18 hr Insulin mixtures 75/25 70/30 50/50 ( NPH / Regular )
  • 85. 3. Intermediate - acting insulins (contd.) Lente insulin Turbid suspension Mixture of 30% semilente insulin 70% ultralente insulin Injected S.C. (only) Onset of action 1 - 3 hr Peak serum level 4 - 8 hr Duration of action 13 - 20 hr
  • 86. 3. Intermediate - acting insulins (contd.) Lente and NPH insulins Are roughly equivalent in biological effects. They are usually given once or twice a day. N.B: They are not used during emergencies (e.g. diabetic ketoacidosis).
  • 87. 4. Long – acting insulins e.g.Insulin glargine Onset of action 2 hr Absorbed less rapidly than NPH&Lente insulins. Duration of action upto 24 hr Designed to overcome the deficiencies of intermediate acting insulins Advantages over intermediate-acting insulins: Constant circulating insulin over 24hr with no pronounced peak. More safe than NPH&Lente insulins due to reduced risk of hypoglycemia(esp.nocturnal hypoglycemia). Clear solution that does not require resuspention before administration.
  • 88.
  • 89. COMPLICATIONS OF INSULIN THERAPY 1. Severe Hypoglycemia (< 50 mg/dl )– Life threatening Overdose of insulin Excessive (unusual) physical exercise A meal is missed 2. Weight gain 3. Local or systemic allergic reactions (rare) 4. Lipodystrophy at injection sites 5. Insulin resistance 6. Hypokalemia
  • 90.